Home-based exercise program to improve physical function for bladder cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates a personalized home-based prehabilitation exercise intervention aimed at improving physical function and surgical outcomes in patients with bladder cancer and upper tract urothelial cancer. Participants are randomized into two groups: one group follows a structured exercise program using the ExerciseRx app, while the other receives standard educational materials. The exercise program includes four weekly sessions focused on core strength and balance, along with personalized step count goals, and is designed to be completed prior to surgery and continued for 90 days post-surgery. The study aims to assess the impact of pre-surgical physical activity on recovery and overall health outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years of age or older
* English-speaking
* Planned treatment with radical cystectomy or radical nephroureterectomy/ureterectomy with or without preceding systemic therapy as indicated by the patient's surgeon with enough time to complete a minimum of 4 weeks of exercises before surgery if enrolled in the (P)REHAB arm
* Willing and able to participate in trial activities

Exclusion Criteria:

* Cognitive/mental impairment that will preclude ability to participate in routine exercise activities. Significant cognitive or memory impairment or baseline dementia that would preclude a patient's ability to follow instructions or reproduce exercises
* Immobility, inability/unwillingness to perform personalized exercise program. Inability to perform exercises safely from seated or standing position at home or recent falls or high fall risk. Neurologic or orthopedic condition(s) that restricts participation in unsupervised home exercises, such as prior stroke with neurologic impairment, weight-bearing precautions, or unwillingness to participate in exercises
* Participants who have nonmuscle-invasive urothelial cancer of the bladder/upper tract anticipating undergoing organ-preserving treatments, or radiographic evidence of metastatic disease involving other organs including brain metastases.
* Patients with predominant histology other than urothelial carcinoma of the bladder or upper tracts (e.g. metastasis from another cancer) who would not otherwise be considered candidates for standard definitive or consolidative surgeries (radical cystectomy, ureterectomy, radical nephroureterectomy) with/without treatment with preoperative/neoadjuvant systemic therapy.
* Uncontrolled or concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Pregnant women are excluded from this study
* Inability to understand or read English
* Lack of access or lack of sufficient facility to use an Android or iOS smart device with the minimum criteria for using ExerciseRx
* Not receiving surgery at UWMC
* Participation in a clinical trial that does not permit enrollment in the Get Moving trial

Where it's running

• Fred Hutch/University of Washington Cancer Consortium
  Seattle, Washington, United States Recruiting

Study contacts

• Principal investigator: Sarah Psutka — Fred Hutch/University of Washington Cancer Consortium
• Study coordinator: Get Moving Research Coordinator
• Email: GetMoving@uw.edu
• Phone: 206-210-4040

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dual-target Nectin-4 and HER2 CAR-NK therapy for advanced urothelial carcinoma

  This treatment will try dual-target CAR-NK cells that recognize Nectin‑4 and HER2 in adults with relapsed or metastatic urothelial carcinoma after standard therapies.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07492628

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Urinary Cell-Free DNA Test for Urothelial Cancer Origin

  This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.

  Recruiting Ruijin Hospital · Shanghai · NCT07888374

• Hospital admissions for blood in the urine

  This international observational project will look at how hospitals manage adults admitted with blood in the urine to see which approaches lead to shorter stays and better outcomes.

  Recruiting British Urology Researchers in Surgical Training · London · NCT07395037

• Intravesical gemcitabine followed by docetaxel for high-grade BCG-unresponsive NMIBC

  This trial tests whether putting gemcitabine then docetaxel directly into the bladder can treat adults with high-grade non-muscle-invasive bladder cancer that did not respond to BCG.

  Recruiting Phase 2 University of Iowa · Iowa City, Iowa · NCT07322263

• Ureteral stent versus no stent for adults having radical cystectomy with an ileal conduit

  This trial tests whether placing temporary ureteral stents at the time of radical cystectomy with ileal conduit reduces post-operative complications compared with not placing stents in adults having cystectomy for bladder or other pelvic cancers.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania and 1 other locations · NCT07234968

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.